免疫性血小板减少症(ITP)是一种自身免疫驱动的疾病,其特征是破坏增加和血小板产生受损,导致出血风险增加。免疫抑制剂是ITP最常见的治疗策略。尽管它们的功效,这些药物通常会引起不可预测的副作用。最近的研究表明,ITP患者的脾脏和血清中的B细胞活化因子(BAFF)水平均升高。Belimumab,BAFF抑制剂,说明了通过干扰BAFF活性和长寿命浆细胞产生来管理ITP的有希望的治疗途径。当将利妥昔单抗与抗BAFF单克隆抗体组合治疗ITP时,临床和实验研究均产生了积极的结果。此外,ianalumab,具有靶向BAFF-R和删除外周BAFF-R+B细胞的双重机制的单克隆抗体,目前正在用于ITP治疗[NCT05885555]。来自新型BAFF抑制剂的即将到来的结果,比如ianalumab,可以为临床医生提供治疗ITP的额外治疗选择。
Immune thrombocytopenia (ITP) is an autoimmune-driven disease characterized by increased destruction and impaired platelet production resulting in an enhanced risk of bleeding. Immunosuppressant agents are the most common treatment strategies for ITP. Despite their efficacy, these medications often cause unpredictable side effects. Recent investigations revealed that patients with ITP exhibit elevated B-cell activating factor (
BAFF) levels in both their spleens and serum. Belimumab, a
BAFF inhibitor, illustrated a promising therapeutic avenue for managing ITP by interfering with
BAFF activity and long-lived plasma cell production. Both clinical and experimental studies have yielded positive outcomes when combining rituximab with an anti-BAFF monoclonal antibody in treating ITP. In addition, ianalumab, a monoclonal antibody with a dual mechanism that targets BAFF-R and deletes peripheral
BAFF-R+ B cells, is currently being used for ITP treatment [NCT05885555]. The upcoming results from novel
BAFF inhibitors, such as ianalumab, could offer clinicians an additional therapeutic option for treating ITP.